Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties
Open Access
- 4 May 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 27 (7) , 657-668
Abstract
Siglecs are transmembrane sialoglycan binding proteins, most of which are expressed on leukocyte subsets and have inhibitory motifs that translate cell surface ligation into immune suppression. In humans, Siglec-8 on eosinophils, mast cells and basophils and Siglec-9 on neutrophils, monocytes and some T-cells, mediate immune cell death, inhibition of immune mediator release and/or enhancement of anti-inflammatory mediator release. Endogenous sialoglycan ligands in tissues, mostly uncharacterized, engage siglecs on leukocytes to inhibit inflammation. Glycan array analyses demonstrated that Siglec-8, Siglec-9 and their mouse counterparts Siglec-F and Siglec-E (respectively) have distinct glycan binding specificities, with Siglec-8 more structurally restricted. Since siglecs are involved in lung inflammation, we studied Siglec-8 and Siglec-9 ligands in human lungs and airways. Siglec-8 ligands are in tracheal submucosal glands and cartilage but not airway epithelium or connective tissues, whereas Siglec-9 ligands are broadly distributed. Mouse airways do not have Siglec-8 ligands, whereas Siglec-9 ligands are on airways of both species. Extraction of human airways and lung followed by electrophoretic resolution and siglec blotting revealed Siglec-8 ligands in extracts of human trachea and cultured tracheal gland cells, but not parenchyma or cultured airway epithelial cells whereas Siglec-9 ligands were extracted from all airway and lung tissues and cells tested. Siglec-8 and Siglec-9 ligands in airways appear to be high molecular weight O-linked sialoglycoproteins. These data reveal differential glycan specificities of Siglec-8, Siglec-9 and their mouse counterparts Siglec-F and Siglec-E, and the tissue distributions and molecular characteristics of Siglec-8 and Siglec-9 sialoglycan ligands on human airways and lungs.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (HL107151)
- Johns Hopkins University Chemistry-Biology Interface Program (T32 GM080189)
This publication has 51 references indexed in Scilit:
- Galactose 6-O-Sulfotransferases Are Not Required for the Generation of Siglec-F Ligands in Leukocytes or Lung TissueJournal of Biological Chemistry, 2013
- Siglecs as sensors of self in innate and adaptive immune responsesAnnals of the New York Academy of Sciences, 2012
- Early Murine T-lymphocyte Activation Is Accompanied by a Switch from N-Glycolyl- to N-Acetyl-neuraminic Acid and Generation of Ligands for Siglec-EJournal of Biological Chemistry, 2011
- Sialidase enhances recovery from spinal cord contusion injuryProceedings of the National Academy of Sciences, 2010
- Polymorphisms in the sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) gene are associated with susceptibility to asthmaEuropean Journal of Human Genetics, 2010
- Eosinophil-Selective Binding and Proapoptotic Effect in Vitro of a Synthetic Siglec-8 Ligand, Polymeric 6′-Sulfated Sialyl Lewis XThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Immunology of asthma and chronic obstructive pulmonary diseaseNature Reviews Immunology, 2008
- Interleukin-5 Priming of Human Eosinophils Alters Siglec-8–Mediated Apoptosis PathwaysAmerican Journal of Respiratory Cell and Molecular Biology, 2008
- Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophilsBlood, 2007
- Determination of Glycolipid–Protein Interaction Specificity2006